Bioclinica, a Princeton-based life science and technology solutions provider, has acquired a Silicon Valley artificial intelligence company, it announced Wednesday.
The deal for Saliency will give Bioclinica advanced AI technology that it can integrate into its Imaging Platform for pharmaceutical and medical device clients, it said in a news release. That will bolster image quality control and interpretation, the company added.
“Clients rely on us for time-sensitive, expert-level image interpretation for their clinical trials, so they can focus on outcomes,” Dan Gebow, Bioclinica’s chief information officer, said in a prepared statement. “We evaluated a variety of medical imaging AI platforms and know the Saliency platform is head and shoulders above others in the market in its ability to deliver value for our clients.”
Financial terms of the deal were not disclosed. The Saliency co-founders, Kevin Thomas and Lukasz Kidzinski, will join Bioclinica’s Image Science team.
